Clinical Trial Update: Lethargic Depression Study [Phase 3]

View source ↗

Summary

The Phase 3 Lethargic Depression Study, sponsored by GlaxoSmithKline, has completed. The study investigated epilepsy and major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Major Depressive Disorder

Snippet

Sponsor: GlaxoSmithKline | Conditions: Epilepsy, Major Depressive Disorder (MDD) | Phase 3 | Status: COMPLETED